Labcorp Holdings Inc. (NYSE:LH) Given Consensus Rating of “Moderate Buy” by Brokerages

Labcorp Holdings Inc. (NYSE:LH) has earned an average rating of “Moderate Buy” from the thirteen analysts that are presently covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation and ten have assigned a buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $302.75.

LH has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. upped their price objective on shares of Labcorp from $319.00 to $330.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 18th. Morgan Stanley restated an “overweight” rating on shares of Labcorp in a research note on Tuesday, February 17th. Robert W. Baird upped their target price on Labcorp from $313.00 to $326.00 and gave the company an “outperform” rating in a report on Wednesday, February 18th. Wall Street Zen raised Labcorp from a “hold” rating to a “buy” rating in a research report on Friday, January 23rd. Finally, Weiss Ratings raised Labcorp from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, February 10th.

Labcorp Trading Up 0.0%

Shares of Labcorp stock opened at $282.57 on Wednesday. The company has a market capitalization of $23.43 billion, a P/E ratio of 27.01, a price-to-earnings-growth ratio of 1.93 and a beta of 1.03. The stock has a fifty day simple moving average of $265.50 and a 200 day simple moving average of $269.31. Labcorp has a 12-month low of $209.38 and a 12-month high of $293.72. The company has a current ratio of 1.42, a quick ratio of 1.23 and a debt-to-equity ratio of 0.60.

Labcorp (NYSE:LH) last posted its quarterly earnings data on Tuesday, February 17th. The medical research company reported $4.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.95 by $0.12. The firm had revenue of $3.52 billion for the quarter, compared to the consensus estimate of $3.56 billion. Labcorp had a net margin of 6.28% and a return on equity of 16.16%. The business’s revenue for the quarter was up 5.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.45 EPS. Labcorp has set its FY 2026 guidance at 17.550-18.250 EPS. On average, sell-side analysts anticipate that Labcorp will post 16.01 earnings per share for the current fiscal year.

Labcorp Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 12th. Stockholders of record on Friday, February 27th will be paid a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date is Friday, February 27th. Labcorp’s payout ratio is presently 27.53%.

Insider Transactions at Labcorp

In other Labcorp news, CEO Adam H. Schechter sold 5,273 shares of the business’s stock in a transaction dated Wednesday, February 11th. The shares were sold at an average price of $284.38, for a total value of $1,499,535.74. Following the transaction, the chief executive officer directly owned 87,343 shares in the company, valued at $24,838,602.34. The trade was a 5.69% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Jonathan C. Meltzer sold 87 shares of the stock in a transaction that occurred on Thursday, February 12th. The shares were sold at an average price of $290.42, for a total transaction of $25,266.54. Following the transaction, the executive vice president directly owned 2,782 shares of the company’s stock, valued at $807,948.44. This represents a 3.03% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.84% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Labcorp

Hedge funds have recently modified their holdings of the stock. Caldwell Trust Co purchased a new stake in Labcorp in the second quarter worth $25,000. Financial Gravity Companies Inc. purchased a new position in shares of Labcorp during the 2nd quarter valued at $26,000. Thurston Springer Miller Herd & Titak Inc. bought a new position in shares of Labcorp during the 4th quarter worth $26,000. Hilton Head Capital Partners LLC bought a new position in shares of Labcorp during the 4th quarter worth $27,000. Finally, JPL Wealth Management LLC purchased a new stake in Labcorp in the 3rd quarter worth about $28,000. Institutional investors own 95.94% of the company’s stock.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.